Cara Therapeutics (CARA) Stock Forecast & Price Target

$0.31 0.00 (0.00%)

(As of 11/22/2024 ET)

Cara Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 5 Analyst Ratings

Sell
0

Hold
5

Buy
0

Based on 5 Wall Street analysts who have issued ratings for Cara Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 5 analysts, 5 have given a hold rating for CARA.

Consensus Price Target

$2.32
660.41% Upside

According to the 5 analysts' twelve-month price targets for Cara Therapeutics, the average price target is $2.32. The highest price target for CARA is $5.00, while the lowest price target for CARA is $1.00. The average price target represents a forecasted upside of 660.41% from the current price of $0.31.

Get the Latest News and Ratings for CARA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cara Therapeutics and its competitors.

CARA Analyst Ratings Over Time

Type	Current Forecast 11/25/23 to 11/24/24	1 Month Ago 10/26/23 to 10/25/24	3 Months Ago 8/27/23 to 8/26/24	1 Year Ago 11/25/22 to 11/25/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	4 Buy rating(s)
Hold	5 Hold rating(s)	6 Hold rating(s)	6 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$2.32	$2.32	$2.32	$15.86
Forecasted Upside	660.41% Upside	765.67% Upside	527.37% Upside	1,515.44% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

CARA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CARA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cara Therapeutics Stock vs. The Competition

Type	Cara Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	660.41% Upside	27,073.49% Upside	7.66% Upside
News Sentiment Rating	Neutral News See Recent CARA News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/13/2024	Canaccord Genuity Group 1 of 5 stars		Reiterated Rating	Buy ➝ Hold	$10.00 ➝ $1.00	+47.17%
6/13/2024	Stifel Nicolaus 4 of 5 stars		Downgrade	Buy ➝ Hold	$6.00 ➝ $1.00	+47.17%
6/13/2024	HC Wainwright 2 of 5 stars	O. Livnat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
6/13/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Stringer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
11/14/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Neutral
5/16/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$6.00 ➝ $4.00	-3.61%
First JFK… next Elon? (Ad) Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger. I share with you in this special investigative documentary.
3/7/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$19.00 ➝ $16.00	+139.16%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 02:21 AM ET.

CARA Forecast - Frequently Asked Questions

: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Cara Therapeutics is $2.32, with a high forecast of $5.00 and a low forecast of $1.00.
: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CARA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CARA, but not buy additional shares or sell existing shares.
: According to analysts, Cara Therapeutics's stock has a predicted upside of 660.41% based on their 12-month stock forecasts.
: Analysts like Cara Therapeutics less than other "medical" companies. The consensus rating for Cara Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CARA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Coins Set to Soar with a Pro-Crypto White House (Ad)

Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…

Click here to reserve your free seat at the Crypto Community Summit

This page (NASDAQ:CARA) was last updated on 11/24/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cara Therapeutics (CARA) Stock Forecast & Price Target